Cramer Calls Pfizer ‘Uninvestible’ After Q3 Beat, Citing No Growth Engine and Seagen Letdown

Cramer casts Pfizer as a bond-like payout with no clear growth engine.

Overview

Pfizer posted $16.65 billion in third-quarter revenue and $0.87 adjusted EPS, topping estimates and lifting full-year guidance to $3.00–$3.15, yet the stock barely moved.
Cramer said the shares sell at roughly eight times earnings and predicted they will continue to trade at that multiple.
He argued Pfizer lacks a growth engine and said the Seagen purchase has not produced the results investors expected.
The CNBC host described investor interest as yield-driven, pointing to a dividend near 7% and calling the stock bond-like.
Cramer criticized CEO Albert Bourla’s dealmaking choices and suggested opportunities were missed even as an upside earnings surprise failed to spark a rally.